---
title: "Lantern Pharma Inc. Q2 2026: Net income $(7.07M), EPS $(0.57) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295929168.md"
description: "Lantern Pharma Inc. reported a Q2 2026 net loss of $7.07M, or $0.57 per share, widening from the prior year's $4.33M loss. The company generated no revenue for the first half of 2026. Key developments include advancing clinical candidates LP-300, LP-184, and LP-284, launching Zeta.ai partnerships, and continuing ADC program collaborations. R&D spending decreased due to lower trial activity, while G&A costs rose."
datetime: "2026-08-14T11:41:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295929168.md)
  - [en](https://longbridge.com/en/news/295929168.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295929168.md)
generator: "portal-rs"
---

# Lantern Pharma Inc. Q2 2026: Net income $(7.07M), EPS $(0.57) — 10-Q Summary

Lantern Pharma Inc. reported results for the quarter ended June 30, 2026, posting a consolidated net loss of $(7.07M), or $(0.57) per share (basic and diluted), versus a net loss of $(4.33M), or $(0.40) per share, in the year‑ago quarter. The company reported no revenue for the six‑month periods ended June 30, 2026 or 2025.

**Financial Highlights**

-   Net income: Consolidated net loss of $(7.07M) for Q2 2026 vs. net loss of $(4.33M) in Q2 2025 (approximately (63%) worse YoY).
-   Diluted EPS: Loss per share, basic and diluted of $(0.57) for Q2 2026 vs. $(0.40) in Q2 2025.
-   Revenue: No revenues recognized for the six‑month periods ended June 30, 2026 or 2025.

**Business Highlights**

-   Clinical pipeline: Advanced three clinical-stage candidates — LP-300, LP-184 (Phase 1a completed) and LP-284 (Phase 1A ongoing).
-   AI commercialization: Launched withZeta.ai and formed Open Medicine AI to commercialize a multi-agent co-scientist platform.
-   Targeted trials: Continued use of RADR® A.I. to refine patient selection, including focusing LP-300 Harmonic™ on the EGFR L858R subgroup to improve trial efficiency.
-   ADC and preclinical work: Continued ADC program development in collaboration with Bielefeld using a cryptophycin payload that has shown promising preclinical potency.
-   Cost and operations: R&D spending declined year over year due to lower trial activity, while G&A investments increased in business development, investor relations and staffing.

Original SEC Filing: Lantern Pharma Inc. \[ LTRN \] - 10-Q - Aug. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [LTRN.US](https://longbridge.com/en/quote/LTRN.US.md)
- [ZETA.US](https://longbridge.com/en/quote/ZETA.US.md)
- [ZETX.US](https://longbridge.com/en/quote/ZETX.US.md)

## Related News & Research

- [Paratus Energy announces Q2 2026 cash dividend of USD 0.22 per share](https://longbridge.com/en/news/297268195.md)
- [WSHP: First half 2026 results released, highlighting platform growth and ongoing user ownership initiatives](https://longbridge.com/en/news/296829514.md)
- [VER: Q2 2026 delivered 6.5% like-for-like revenue growth and strong gross margin, with 2026 guidance reaffirmed](https://longbridge.com/en/news/297124510.md)
- [SoftwareOne attaches full H1 2026 report in correction to earlier release](https://longbridge.com/en/news/297010247.md)
- [Cemat publishes H1 2026 interim report](https://longbridge.com/en/news/297006906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**